BEGIN:VCALENDAR VERSION:2.0 PRODID:-//PYVOBJECT//NONSGML Version 1//EN BEGIN:VTIMEZONE TZID:Europe/Berlin BEGIN:STANDARD DTSTART:20001029T030000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10 TZNAME:CET TZOFFSETFROM:+0200 TZOFFSETTO:+0100 END:STANDARD BEGIN:DAYLIGHT DTSTART:20000326T020000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3 TZNAME:CEST TZOFFSETFROM:+0100 TZOFFSETTO:+0200 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT UID:20261107T075500Z - 95516@eu652a.odoo.com DTSTART;TZID=Europe/Berlin:20260830T183000 DTEND;TZID=Europe/Berlin:20260830T213000 CREATED:20261107T075500Z DESCRIPTION:The Economics of Medical Breakthroughs\nOver view ⏱️Schedule: Doors 18:30 → Talk 19:00→ Q&A → Mingle 🌐Lang uage: English Regenerative medicines may do more than manage symptoms — they can target the underlying cause of disease\, prevent irreversible dam age\, and change the course of lifelong conditions. But they also raise di fficult questions. When a single treatment can cost more than several hous es\, healthcare systems must assess not only whether it works\, but for wh om\, for how long\, and whether its price represents a responsible use of public resources. Health economist Andrea Greco studies how these difficul t decisions are made. His research examines how healthcare systems balance scientific innovation\, patient needs\, evidence uncertainty\, and limite d healthcare budgets. In this talk\, he guides the audience through Health Technology Assessment (HTA) — the process used to evaluate whether new treatments provide sufficient clinical and societal value to be funded and made available to patients. What we'll coverHealth Technology Assessment (HTA): the process behind new medicines — and why almost every major tre atment passes through it before it ever reaches youWhy the most exciting b reakthroughs are often the hardest to pay forWhat happens when a treatment 's evidence looks promising but the long-term picture is still unclearMana ged entry agreements — how systems pay for a medicine now while gatherin g more evidence on whether it actually deliversWhat the price we're willin g to pay for medicine really says about the kind of society we are Speaker Andrea Greco Health economist and PhD candidate at UMC Utrecht and Utrech t University Andrea researches how healthcare systems decide which new tre atments — including gene and cell therapies — are worth paying for. Hi s work focuses on advanced therapies where clinical promise\, high costs\, and long-term uncertainty collide. He has conducted research across Europ ean [...] DTSTAMP:20261107T075500Z LOCATION:Kwakersplein 2\, 1053 TZ Amsterdam\, Netherlands SUMMARY:The Economics of Medical Breakthroughs X-ALT-DESC;FMTTYPE=text/html:The Economics of Medical Breakt hroughs\nOverview ⏱️Schedule: Doors 18:30 → Talk 19:00→ Q&A → Mingle 🌐Language: English Regenerative medicines may do more than m anage symptoms — they can target the underlying cause of disease\, preve nt irreversible damage\, and change the course of lifelong conditions. But they also raise difficult questions. When a single treatment can cost mor e than several houses\, healthcare systems must assess not only whether it works\, but for whom\, for how long\, and whether its price represents a responsible use of public resources. Health economist Andrea Greco studies how these difficult decisions are made. His research examines how healthc are systems balance scientific innovation\, patient needs\, evidence uncer tainty\, and limited healthcare budgets. In this talk\, he guides the audi ence through Health Technology Assessment (HTA) — the process used to ev aluate whether new treatments provide sufficient clinical and societal val ue to be funded and made available to patients. What we'll coverHealth Tec hnology Assessment (HTA): the process behind new medicines — and why alm ost every major treatment passes through it before it ever reaches youWhy the most exciting breakthroughs are often the hardest to pay forWhat happe ns when a treatment's evidence looks promising but the long-term picture i s still unclearManaged entry agreements — how systems pay for a medicine now while gathering more evidence on whether it actually deliversWhat the price we're willing to pay for medicine really says about the kind of soc iety we are Speaker Andrea Greco Health economist and PhD candidate at UMC Utrecht and Utrecht University Andrea researches how healthcare systems d ecide which new treatments — including gene and cell therapies — are w orth paying for. His work focuses on advanced therapies where clinical pro mise\, high costs\, and long-term uncertainty collide. He has conducted re search across European [...] END:VEVENT END:VCALENDAR